Intellia Therapeutics (NTLA) Times Interest Earned (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Times Interest Earned of -$1.04 for Q1 2026, down 22.65% year-over-year from -$1.34 in Q1 2025, and up 99.95% quarter-over-quarter from -$1974.2 in Q4 2025.
Intellia Therapeutics (NTLA) Times Interest Earned (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Times Interest Earned for 12 consecutive years, with -$1.04 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 22.65% year-over-year to -$1.04; the TTM figure through Mar 2026 stood at -$4.34 (down 14.6% YoY), while the FY2025 annual figure was -$0.48, up 29.32% from the prior year.
- Times Interest Earned grew to -$1.04 in Q1 2026 per NTLA's latest filing, from -$1974.2 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.24 in Q4 2022 and bottomed at -$1974.2 in Q4 2025.
- Historically, Times Interest Earned has averaged -$141.97 across 5 years, with a median of -$1.93 in 2023.
- Annual changes were most pronounced in 2024 — Times Interest Earned tumbled 9910.68% — and 2025, when it surged 92.64%.
- Intellia Therapeutics' Times Interest Earned stood at -$0.24 in 2022, then slumped by 1508.83% to -$3.89 in 2023, then plunged by 9910.68% to -$389.85 in 2024, then sank by 406.4% to -$1974.2 in 2025, then soared by 99.95% to -$1.04 in 2026.
- Business Quant data shows NTLA's Times Interest Earned at -$1.04 in Q1 2026, -$1974.2 in Q4 2025, and -$0.95 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -1.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.30 |
| Mar 31, 2026 | -1.04 |
| Dec 31, 2025 | -1,974.20 |
| Sep 30, 2025 | -0.95 |
| Jun 30, 2025 | -7.03 |
| Mar 31, 2025 | -0.85 |
| Dec 31, 2024 | -389.85 |
| Sep 30, 2024 | -12.87 |
| Jun 30, 2024 | -8.79 |
| Mar 31, 2024 | -4.13 |
| Dec 31, 2023 | -3.89 |
| Sep 30, 2023 | -3.29 |
| Jun 30, 2023 | -1.93 |
| Mar 31, 2023 | -1.89 |
| Dec 31, 2022 | -0.24 |
| Sep 30, 2022 | -0.90 |
| Jun 30, 2022 | -0.93 |
| Mar 31, 2022 | -0.70 |
| Dec 31, 2021 | -0.26 |
| Sep 30, 2021 | -0.12 |